Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade and Lenalidomide in Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
NCT02312102Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bortezomib and lenalidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Feb 2015; status: completed.
02
Drugs
bortezomiblenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02312102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02312102.